Lenalidomide for the treatment of relapsed and refractory multiple myeloma

Lenalidomide is an amino-substituted derivative of thalidomide with direct antiproliferative and cytotoxic effects on the myeloma tumor cell, as well as antiangiogenic activity and immunomodulatory effects. Together with the introduction of bortezomib and thalidomide, lenalidomide has significantly...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Donk, Niels WCJ, Görgün, Güllü, Groen, Richard WJ, Jakubikova, Jana, Mitsiades, Constantine S, Hideshima, Teru, Laubach, Jacob, Nijhof, Inger S, Raymakers, Reinier A, Lokhorst, Henk M, Richardson, Paul G, Anderson, Kenneth C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430086/
https://www.ncbi.nlm.nih.gov/pubmed/22956884
http://dx.doi.org/10.2147/CMAR.S27087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430086/
https://www.ncbi.nlm.nih.gov/pubmed/22956884
http://dx.doi.org/10.2147/CMAR.S27087

Ejemplares similares